Tag: pricing

Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription

Unveiling a comprehensive Excel database, this product delves into Thailand's burgeoning data center market, offering in-depth analysis of 32 existing and 17 upcoming colocation data centers across key locations like Bangkok, Chon Buri, Pathum Thani, and Saraburi. Key insights include projected white-floor space, current and future IT load capacities (2025-2028), and pricing for various colocation options. Highlighting investment trends, the upcoming data center capacity will surpass 650MW, with Bangkok leading current capacities over 100MW and future investments expected to exceed $2.3 billion by 2027. Ideal for REITs, contractors, and tech consultancies, this resource is essential for anyone targeting Thailand's data center market.

FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses.

SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company’s Series H Convertible Preferred Stock (“Preferred Stock”), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an exercise price of $25.00 per share (the “Warrants”). The combined public Offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00 (the “Offering”). The Preferred Stock is convertible into the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a conversion price of $2.50 per share. The closing of the Offering is expected to occur on or about July 2, 2025, subject to the satisfaction of customary closing conditions.